689148-14-9

Upstream product

• 124-40-3 dimethyl amine 
• 146070-34-0 2-fluoro-4-(trifluoromethyl)benzonitrile 
• 1813-33-8 2-chloro-4-trifluoromethyl-benzonitril 

Downstream Products

• 1341124-11-5 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2-oxoindolin-4-yl)urea 
• 1338064-85-9 1-(4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b] [1,4]oxazin-8-yl)urea 
• 1338065-37-4 C₁₁H₁₁F₃N₂O 
• 1338064-84-8 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-8-yl)urea 
• 1338064-67-7 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxobenzo[d]oxazol-4-yl)urea 
• 1338065-36-3 2-(aminomethyl)-5-(trifluoromethyl)-N,N-dimethyl-benzenamine 
• 1338064-41-7 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea 

Relevant academic research and scientific papers

"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"

The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active

TRPV1 vanilloid receptor antagonists with a bicyclic portion

The invention discloses compounds of formula I wherein Y s selected from a group of formula and W, Q, n, R1, R2, R3, U1-U5 have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1. 1.

AMIDE COMPOUNDS

A compound of the formula (I) wherein R1 is hydrogen, lower alkyl, lower alkenyl, halo(lower)alkyl, cyclo(lower)alkyl, lower alkoxy, lower alkylthio, acyl, optionally substituted aryl or NR3R4; R2 is hydrogen; or aryl or heteroaryl, each of which may be substituted; X is direct bond or bivalent residue derived from piperazine; Y is -(A1)n#191-(A2?)?m#191-, wherein n and m are independently 0 or 1); is bivalent residue derived from arene or heteroarene; and is bivalent residue derived from arene or heteroarene, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.